-

About

Dr. Dagley is a globally recognised expert in mass spectrometry-based proteomics, with expertise in translational biofluid proteomics. She earned her PhD in 2014 from the University of Melbourne under the supervision of Prof. Tony Purcell. During her PhD, she was awarded funding from multiple sources to undertake part of her training at the University of Toronto with Prof. Andrew Emili, where she gained advanced expertise in mass spectrometry technologies.

Since 2021, she has served as Head of the Proteomics Facility at the Walter and Eliza Hall Institute of Medical Research (WEHI), where she oversees a state-of-the-art mass spectrometry platform and leads a multidisciplinary team delivering end-to-end proteomics support. Under her leadership, the facility has strengthened its role as a highly collaborative proteomics research platform supporting projects across cancer, immune disorders and neurodegenerative disease.

Dr. Dagley has contributed to 70+ peer-reviewed publications (including Nature Immunology, Science, Blood),including 8 as first/co-first author and 2 as senior author, reflecting sustained productivity and leadership in collaborative proteomics.  She has a current h-index of 29, more than 3,500 citations, patent-linked discovery, and multiple national and international collaborations. She also provides scientific leadership through service roles with the Australasian Proteomics Society and the Human Proteome Organisation. Her scientific excellence has been recognised through several prestigious honours, including the 2017 Ken Mitchelhill Young Investigator Award, and finalist positions in the 2016 Bupa Health Foundation Emerging Health Researcher Award and the 2017 Women of the Future Award.

Publications

Selected publications from Dr Laura Dagley

Magtoto CM, Mieruszynski S, Dong H, Ng AP, Di Rago L, Kueh AJ, Brzozowski M, Grohmann C, Walker JR, Chua NK, Dagley LF, Ciulli A, Lessene G, Herold MJ, Heath JK, Silke J, Feltham R. The benchmarking and application of tag-degraders in vivo to validate therapeutic targets. Nature Communications. 2026;:10.1038/s41467-026-73681-1

Schenk P, Devine SM, Cobbold SA, Geoghegan ND, Kyran EL, Ang C-S, Alexandrovics JA, Calleja DJ, Multari DH, Vaibhav V, Lu BGC, Klemm TA, Dagley LF, Lowes KN, Williamson NA, Eichhorn PJA, Ng AP, Feltham R, Komander D. Global analysis of cancer cell responses to USP9X inhibition. The EMBO Journal. 2026;45(9):10.1038/s44318-026-00742-y

Marapana DS, Lopaticki S, Balan B, Reaksudsan K, Cobbold SA, Geoghegan ND, Khurana S, Scally SW, Hickey P, Jayakrishnan N, Vaibhav V, Spall S, Yousef JM, Dagley LF, Goodman CD, Cozijnsen A, McFadden GI, Rogers KL, Jex A, Komander D, McCarthy JS, Tonkin CJ, Dixon MWA, Cowman AF. GID/CTLH E3 ligase complex control cell fate programs for sexual development of Plasmodium falciparum. Nature Communications. 2026;17(1):10.1038/s41467-026-69183-9

Edwards J, Multari DH, Dite T, Binos S, Shugg C, Webb AI, Dagley LF, Emery‐Corbin SJ. Plasma Proteomics Across Three Generations of Mass Spectrometry Instruments: Lessons for Biofluid Method Optimisation. Proteomics. 2026;:10.1002/pmic.70127

Larrea-Sebal A, Dai C, Brenes AJ, Korff K, Neely BA, Geyer PE, Dagley LF, Unwin RD, Naba A, MacCoss MJ, Guo T, Deutsch EW, Martin C, Schwenk JM, Perez-Riverol Y. Blood proteomics: insights from public data. Genome Biology. 2026;27(1):10.1186/s13059-026-04027-9

Dorstyn L, Lim Y, Scanlan J, McLennan E, De Bellis D, Katschner M, Finnie J, Emery-Corbin S, Yousef J, Dagley LF, Kok CH, Shah SS, Takahashi C, Febbraio MA, Kumar S. Caspase-2 deficiency drives pathogenic liver polyploidy and increases age-associated hepatocellular carcinoma in mice. Science Advances. 2026;12(1):10.1126/sciadv.aeb2571

Shibu MA, Shami GJ, Hanssen E, Carmo OMS, Vaibhav V, Yousef J, Dagley LF, McCarthy J, Dixon MWA. MAHRP2 is required for tether formation and cytoadherence in Plasmodium falciparum infected red blood cells. Frontiers in Cellular and Infection Microbiology. 2026;16:10.3389/fcimb.2026.1675134

Keating N, Doggett K, Bidgood GM, Meza Guzman LG, Dagley LF, Li K, Williams BE, Gabrielyan A, Alvarado C, Broomfield BJ, Duckworth BC, Hockings C, Yousef J, Leong E, Morris R, Kueh A, Garnham AL, Giner G, Casanova J-L, Boisson-Dupuis S, Babon JJ, Linossi EM, Tate MD, Groom JR, Nicholson SE. ARAP2 regulates responses to interferon-gamma by restricting SOCS1. Cell Reports. 2025;44(12):10.1016/j.celrep.2025.116667

Horne CR, Wang T, Young SN, Dite TA, Nyvall HG, Suresh S, Davies KA, Castro AG, Vaibhav V, Mather LJ, Dagley LF, Belousoff MJ, Manning G, Means AR, Burke JE, Petersen J, Scott JW, Murphy JM. Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity. Biochemical Journal. 2025;482(23):10.1042/bcj20253431

Liu H, Francis L, Dagley LF, Cobbold SA, Webb AI, Komander D, Villadangos JA, Mintern JD. Major histocompatibility class II in murine antigen presenting cells is modified with a branched K63 and K11-linked ubiquitin chain. Scientific Reports. 2025;15(1):10.1038/s41598-025-25817-4

Interested in supporting our research?

Your support will help WEHI’s researchers make discoveries and find treatments to ensure healthier, longer lives for you and your loved ones.

Contact our friendly team to find out how you can help.

"*" indicates required fields